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MaOBJECTIVES This study examined the relationship between income inequality and heart failure outcomes.
BACKGROUND The income inequality hypothesis postulates that population health is inﬂuenced by income distribu-
tion within a society, with greater inequality associated with worse outcomes.
METHODS This study analyzed heart failure outcomes in 2 large trials conducted in 54 countries. Countries were divided
by tertiles of Gini coefﬁcients (where 0% represented absolute income equality and 100% represented absolute income
inequality), and heart failure outcomes were adjusted for standard prognostic variables, country per capita income,
education index, hospital bed density, and health worker density.
RESULTS Of the 15,126 patients studied, 5,320 patients lived in Gini coefﬁcient tertile 1 countries (coefﬁcient: <33%),
6,124 patients lived in tertile 2 countries (33% to 41%), and 3,772 patients lived in tertile 3 countries (>41%). Patients in
tertile 3 were younger than tertile 1 patients, were more often women, and had less comorbidity and several indicators of
less severe heart failure, yet the tertile 3-to-1 hazard ratios (HRs) for the primary composite outcome of cardiovascular
death or heart failure hospitalization were 1.57 (95% conﬁdence interval [CI]: 1.38 to 1.79) and 1.48 for all-cause death
(95% CI: 1.29 to 1.71) after adjustment for recognized prognostic variables. After additional adjustments were made for
per capita income, education index, hospital bed density, and health worker density, these HRs were 1.46 (95% CI: 1.25 to
1.70) and 1.30 (95% CI: 1.10 to 1.53), respectively.
CONCLUSIONS Greater income inequality was associated with worse heart failure outcomes, with an impact similar
to those of major comorbidities. Better understanding of the societal and personal bases of these ﬁndings may suggest
approaches to improve heart failure outcomes. (J Am Coll Cardiol HF 2019;7:336–46) © 2019 The Authors. Published
by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 2213-1779 https://doi.org/10.1016/j.jchf.2018.11.005
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337AB BR E V I A T I O N S
AND ACRONYM S
eGFR = estimated glomerular
ﬁltration rate
HFrEF = heart failure with
reduced ejection fraction
KCCQ = Kansas City
Cardiomyopathy Questionnaire
LVEF = left ventricular
ejection fraction
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
NYHA = New York Heart
AssociationH eart failure (HF) is now recognized as a ma-jor public health problem not only in West-ern nations but also in low- and middle-
income countries, reﬂecting the demographic
changes and the epidemiological transition to non-
communicable diseases occurring in the latter coun-
tries (1). The growing recognition of the
international importance of HF has been accompa-
nied by studies highlighting the considerable differ-
ences in HF outcomes that exist among countries
(2,3). Understanding the basis of these differences
may help in tackling this increasing global problem.
Some of the geographical variations in identiﬁed out-
comes are attributable to differences in recognized
prognostic factors such age, HF severity, and comor-
bidity. Other factors may also be pertinent, such as in-
come inequality, which varies considerably
internationally and is often particularly marked in
low- and middle-income countries. The income
inequality hypothesis postulates that population
health is inﬂuenced by the degree to which income
is unevenly distributed within a society (4,5). This hy-
pothesis was developed to explain why large differ-
ences in population health are still observed in
developed countries with high levels of income, as
measured by gross domestic product (GDP) per capita
(6,7). A variety of studies has shown a negative corre-
lation between income inequality and life expec-
tancy, infant mortality, and the incidence,
prevalence, and burden of several diseases. The
PARADIGM-HF (Prospective comparison of ARNI
[Angiotensin Receptor Neprilysin Inhibitor] with
ACEI [Angiotensin-Converting Enzyme Inhibitor] to
Determine Impact on Global Mortality and morbidity
in Heart Failure) and the ATMOSPHERE (Aliskiren
Trial to Minimize OutcomeS in Patients with Heart
Failure) trials were 2 of the largest clinical trials in pa-
tients with HF with reduced ejection fraction (HFrEF)
(8,9). The present study analyzed a pooled cohort of
15,216 participants from 54 of the 55 countries world-
wide who were enrolled in the 2 trials to examine the
potential association among different levels of in-
come inequality and clinical characteristics and out-
comes in patients with HFrEF.SEE PAGE 347METHODS
TRIALS AND PARTICIPANTS. The design, baseline
characteristics, and outcomes of the PARADIGM-HF
and ATMOSPHERE trials have been published and
are brieﬂy described here (8,9). The inclusion andexclusion criteria of the 2 trials were almost
identical. Patients were eligible at screening
if they were $18 years of age and they had
New York Heart Association (NYHA) func-
tional class II to IV, a left ventricular ejec-
tion fraction (LVEF) #35% (changed
from #40% initially PARADIGM-HF by
amendment), elevated concentrations of
natriuretic peptide (the cutoff level was in-
dependent of atrial ﬁbrillation), and were
taking an angiotensin-converting enzyme
(ACE) inhibitor or an angiotensin receptor
blocker (ARB) with a beta-blocker (unless
contraindicated or not tolerated) and a
mineralocorticoid receptor antagonist, if indicated.
Exclusion criteria at screening included symptom-
atic hypotension or systolic blood pressure
(SBP) <95 mm Hg (<90 mm Hg in ATMOSPHERE),
an estimated glomerular ﬁltration rate (eGFR) <30
ml/min per 1.73 m2 (<35 in ATMOSPHERE), and a
potassium concentration of >5.4 mmol/l (>5.2 in
ATMOSPHERE). The trial was approved by the
ethics committees at all participating centers in 47
countries in PARADIGM-HF and in 43 countries
in ATMOSPHERE. All patients provided written
informed consent.
On trial entry, ongoing therapy with an ACE in-
hibitor or ARB was stopped, and patients entered a
sequential run-in, ﬁrst receiving enalapril, followed
by sacubitril/valsartan in PARADIGM-HF and enalap-
ril, followed by the combination of enalapril plus
aliskiren in ATMOSPHERE. Patients who tolerated
both of the run-in periods were randomly assigned to
receive double-blinded therapy with sacubitril/val-
sartan or enalapril in a 1:1 ratio in PARADIGM-HF
or enalapril or aliskiren or both drugs in a 1:1:1 ratio
in ATMOSPHERE. PARADIGM-HF ran from December
2009 to May 2014, and ATMOSPHERE ran from
May 2009 to October 2015 (median follow-up in-
tervals were 27 months and 36.6 months, respec-
tively) (8,9).
STUDY GROUPS. The impact of income inequality
was evaluated using the Gini coefﬁcient, which is
derived from the Lorenz curve (Online Figure S1), in
which 0 (0%) indicates absolute income equality and
1 (100%) indicates absolute income inequality. For
most countries, Gini coefﬁcients were obtained from
the United Nations Development Programme (UNDP)
(10). Data from 2003 were used to account for a lag
effect, whereby a state of inequality dating back 15
years might have had a stronger association with
health than current income inequality (11). For
TABLE 1 Baseline Characteristics, Clinical Features, Investigations, and Treatment According to Tertiles of Gini Coefﬁcient
Gini Tertile 1 Gini Tertile 2 Gini Tertile 3
Least Inequality
(n ¼ 5,320)
Intermediate Group
(n ¼ 6,124)
Greatest Inequality
(n ¼ 3,772)
Baseline characteristics
Gini coefﬁcient <33 33–41 >41
Number of countries 18 19 17
Age, yrs 66.3  10.3 62.8  11.6 61.0  12.2
Age group, yrs
#40 78 (1.5) 254 (4.1) 215 (5.7)
41-55 690 (13.0) 1,255 (20.5) 963 (25.5)
56-70 2,556 (48.0) 2,932 (47.9) 1,716 (45.5)
>70 1,996 (37.5) 1,683 (27.5) 878 (23.3)
Females 1,118 (21.0) 1,273 (20.8) 936 (24.8)
Region
North America 0 (0.0) 779 (12.7) 0 (0.0)
Latin America 0 (0.0) 187 (3.1) 2,365 (62.7)
Western Europe and other 2,315 (43.5) 1,328 (21.7) 311 (8.2)
Central Europe 2,570 (48.3) 2,136 (34.9) 64 (1.7)
Asia-Paciﬁc 435 (8.2) 1,694 (27.7) 1,032 (27.4)
Per capita income, US$ 31,582  18,675 20,714  17,704 9,980  5,706
Percentage of national GDP spent on health care 9.1  1.9 7.8  3.4 6.8  1.5
HDI 0.890 (0.834–0.920) 0.803 (0.676–0.877) 0.737 (0.723–0.780)
Education index 0.847 (0.822–0.898) 0.814 (0.635–0.852) 0.664 (0.616–0.709)
Life index 0.924 (0.847–0.935) 0.817 (0.740–0.931) 0.855 (0.834–0.863)
Income index 0.865 (0.816–0.917) 0.830 (0.657–0.879) 0.725 (0.719–0.785)
Hospital beds per 1,000 6.4 (6.0–8.2) 2.9 (1.0–6.5) 2.5 (1.6–3.8)
Health workers per 1,000* 6.0 (4.7–8.7) 4.5 (1.4–6.1) 1.9 (1.8–4.1)
SBP, mm Hg 125  16.9 122  16.5 120  16.3
HR, beats/min 71.5  12.8 72.5  11.8 71.8  12.2
BMI, kg/m2 28.6  5.2 27.7  5.8 26.9  5.2
Weight category†
Underweight 37 (0.7) 179 (2.9) 88 (2.3)
Normal 1,267 (23.8) 1,877 (30.6) 1,335 (35.4)
Overweight 2,158 (40.6) 2,182 (35.6) 1,448 (38.4)
Obese 1,853 (34.8) 1,869 (30.5) 894 (23.7)
Medical history
Hypertension 3,733 (70.2) 4,072 (66.5) 2,324 (61.6)
Diabetes 1,804 (33.9) 2,011 (32.8) 954 (25.3)
Atrial ﬁbrillation, ECG 1,704 (32.0) 1,254 (20.5) 639 (16.9)
Atrial ﬁbrillation history 2,496 (46.9) 2,030 (33.2) 885 (23.5)
Unstable angina 626 (11.8) 788 (12.9) 264 (7.0)
Myocardial infarction 2,292 (43.1) 3,021 (49.3) 1,111 (29.5)
Stroke 490 (9.2) 466 (7.6) 245 (6.5)
COPD 789 (14.8) 820 (13.4) 222 (5.9)
Renal disease 846 (15.9) 929 (15.2) 233 (6.2)
ECG ﬁndings
LBBB 1,023 (19.2) 1,219 (21.6) 815 (21.6)
RBBB 601 (11.3) 564 (9.2) 405 (10.7)
QRS duration, ms 119.9  34.7 114.9  35.5 116.5  36.7
Smoking/alcohol
Smoking status
Never smoked 2,536 (47.7) 3,401 (55.5) 2,129 (56.4)
Ex-smoker 1,970 (37.0) 1,949 (31.8) 1,175 (31.2)
Current smoker 814 (15.3) 774 (12.6) 468 (12.4)
Alcohol, drinks/day‡
<1 4,368 (82.1) 5,496 (89.8) 3,492 (92.6)
1-2 788 (14.8) 521 (8.5) 204 (5.4)
>2 164 (3.1) 105 (1.7) 76 (2.0)
Continued on the next page
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TABLE 1 Continued
Gini Tertile 1 Gini Tertile 2 Gini Tertile 3
Least Inequality
(n ¼ 5,320)
Intermediate Group
(n ¼ 6,124)
Greatest Inequality
(n ¼ 3,772)
Heart failure: clinical features, investigations, drugs and devices
Gini coefﬁcient <33 33–41 >41
Time since HF diagnosis, yrs
<1 1,526 (28.7) 1,928 (31.5) 1,357 (36.0)
1-5 1,964 (36.9) 2,278 (37.2) 1,514 (40.1)
>5 1,829 (34.4) 1,915 (31.3) 901 (23.9)
HF cause
Ischemic 3,251 (61.1) 4,107 (67.1) 1,521 (40.3)
Nonischemic 1,573 (29.6) 1,428 (23.3) 1,726 (45.8)
Unknown 496 (9.3) 589 (9.6) 525 (1.4)
Prior hospitalization for HF 3,331 (62.6) 3,686 (60.2) 2,292 (60.8)
NYHA functional class§
I/II 3,748 (68.6) 4,264 (69.7) 3,231 (85.7)
III 1,627 (30.6) 1,793 (29.3) 520 (13.8)
IV 45 (0.9) 58 (1.0) 17 (0.5)
KCCQ, clinical summary score 77.1 (60.4–90.0) 76.0 (58.9–89.6) 87.5 (75.0–95.8)
Dyspnea on effort 4,642 (87.3) 5,387 (88.2) 2,997 (79.5)
Orthopnea 267 (5.0) 428 (7.0) 272 (7.2)
PND 345 (6.5) 276 (4.5) 129 (3.4)
Edema 1,213 (22.8) 1,437 (23.5) 489 (13.0)
Third heart sound 409 (7.7) 748 (12.2) 200 (5.3)
JVD 590 (11.1) 457 (7.5) 422 (11.2)
LVEF 29.9  5.7 28.9  6.1 28.0  6.0
LVH 852 (16.0) 1,693 (27.6) 950 (25.2)
NT-proBNP, pg/ml 1,358 (766–2,540) 1,424 (755–2,816) 1,500 (803–3,130)
Hemoglobin, g/l 140.6  14.8 136.7  17.0 138.8  16.0
eGFR, ml/min per 1.73 m2 68.1  19.8 70.3  22.3 74.7  24.6
eGFR, <60 ml/min per m2 1,861 (35.0) 1,994 (32.6) 981 (26.0)
Drug, devices, other therapy
Diuretics 4,342 (81.6) 4,903 (80.1) 2,945 (78.1)
Digitalis 1,374 (25.8) 1,955 (31.9) 1,395 (37.0)
Beta-blocker 4,995 (93.9) 5,591 (91.3) 3,489 (92.5)
MRA 2,381 (44.8) 2,660 (43.4) 2,162 (57.3)
ACE inhibitor pre-randomization 4,772 (89.7) 5,434 (88.7) 3,191 (84.6)
ARB pre-randomization 621 (11.7) 717 (11.7) 590 (15.6)
Statin 3,146 (59.1) 3,741 (61.1) 1,437 (38.1)
Anticoagulants 2,426 (45.6) 1,717 (28.0) 631 (16.7)
Aspirin 2,469 (46.4) 3,393 (55.4) 1,978 (52.4)
Prior PCI 1,384 (26.0) 1,232 (20.1) 510 (13.5)
Prior CABG 969 (18.2) 1,015 (16.6) 278 (7.4)
Conventional pacemaker 780 (14.7) 709 (11.6) 297 (7.9)
ICD or CRT-D 1,131 (21.3) 986 (16.1) 165 (4.4)
CRT-P or CRT-D 442 (8.3) 417 (6.8) 101 (2.7)
Values are n (%), median (IQR), or mean  SD. *Taking into account only physician and nurses/midwives’ density per 1,000 population. †29 were missing. ‡One drink equals 12
oz beer, 8 oz malt liquor, 5 oz wine, 1.5 ounces, or a shot of spirits or liquor. §13 values were missing.
ACE inhibitor ¼ angiotensin angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft;
COPD ¼ chronic obstructive pulmonary disease; CRT ¼ cardiac resynchronization therapy; D ¼ deﬁbrillator; ECG ¼ electrocardiography; eGFR ¼ estimated glomerular ﬁltration
rate; GDP ¼ gross domestic product; HDI ¼ human development index; HF ¼ heart failure; HR ¼ heart rate; ICD ¼ implantable cardioverter cardioverter-deﬁbrillator; IQR ¼
inter quartile range; JVD ¼ jugular venous distension; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection
fraction; LVH ¼ left ventricular hypertrophy; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ N terminal–pro B-type natriuretic peptide; NYHA ¼ New York Heart
Association; P ¼ pacemaker; PCI ¼ percutaneous coronary intervention; PND ¼ paroxysmal nocturnal dyspnea; RBBB ¼ right bundle branch block; SBP ¼ systolic blood
pressure; US$ ¼ U.S. dollars.
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339countries where a Gini coefﬁcient for 2003 was un-
available, a value from the year closest to 2003 was
used. Gini coefﬁcients for Hong Kong, Japan, Korea,
and Singapore were derived from other sources.Taiwan was excluded from the analysis because social
indicators could not be derived from UNDP and
because reports from other sources were inconsistent
and unreliable.
FIGURE 1 World Map Showing Participating Countries According to Tertiles of Gini Coefﬁcient
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340Patients were divided into 3 groups by tertiles ac-
cording to the distribution of Gini coefﬁcients. Group
1 countries (least inequality) had a Gini coefﬁcient
of <33, group 2 consisted of those countries with Gini
coefﬁcients between 33 and 41 and group 3 countries
(greatest inequality) had Gini coefﬁcients of >41. The
association between income inequality and outcomes
was also tested using the Gini coefﬁcient as a
continuous variable.
OTHER SOCIOECONOMIC INDICATORS. To adjust
for other socioeconomic variables, additional infor-
mation was also collected, including national per
capita income (in US$ from the World Bank) (12),
hospital bed density (from The World Factbook) (13),
and health worker density (from the World Health
Organization) (14) per 1,000 population. The educa-
tion index was derived from the Human Development
Index from the UNDP database (15), for further anal-
ysis of outcomes, as discussed subsequently. To
derive health worker density, the average densities of
physicians and nurses/midwives were used as ﬁgures
for other types of health care workers that were not
uniformly available from all countries. All ﬁgures
were ascertained for 2013 or the closest year to 2013.
OUTCOMES. The primary outcome for both trials was
the composite value of the ﬁrst hospitalization for HF
or cardiovascular death. In the present study, the
associations between income inequality, as reﬂected
in the Gini coefﬁcient, the risk of the primaryoutcome and each of its components, and all-cause
mortality were investigated. All endpoints were
adjudicated by the same clinical endpoint committee
according to pre-speciﬁed criteria.
STATISTICAL ANALYSIS. Baseline characteristic
values are proportions, mean  SD, and median
(interquartile range [IQR]). Statistical methods used
to analyze baseline characteristics were analysis of
variance, the chi-square test, and the Kruskal-Wallis
rank test for nonparametric values. Competing risk
regression was carried out using the Fine-Gray model
to analyze the outcomes of interest, using 3 models
(16). All-cause mortality was analyzed using Cox
regression. Model 1 was used to calculate the crude
hazard ratio (HR) for each outcome. Model 2 ﬁtted
age, sex, heart rate, SBP, body mass index, NYHA
functional class, LVEF, eGFR, and N-terminal pro–B-
type natriuretic peptide (NT-proBNP). Model 3 ﬁtted
per capita income, education index, hospital bed
density, and health worker density, in addition to the
variables used in Model 2. Results from a multilevel
Cox regression model were compared with those from
another Cox model, which adjusted only for region,
and found very little variability to account for random
effects (17). Consequently, all models were adjusted
for region along with randomized treatment at base-
line. Schoenfeld residuals were used to test the pro-
portional hazards assumption. Values of p < 0.05
were considered signiﬁcant. All analyses were
TABLE 2 Clinical Outcomes of the PARADIGM-HF and ATMOSPHERE Trials According to
Tertiles of Gini Coefﬁcient
Gini Tertile 1 Gini Tertile 2 Gini Tertile 3
Least Inequality
(n ¼ 5,320)
Intermediate
Group
(n ¼ 6,124)
Greatest
Inequality
(n ¼ 3,772)
Gini coefﬁcient <33 33-41 >41
Primary composite outcome
Events 1,480 (27.8) 1,694 (27.7) 1,138 (33.7)
Event rates per 100 person-yrs
(95% CI)
10.9 (10.4–11.5) 11.7 (11.2–12.3) 13.7 (12.9–14.5)
Unadjusted HR 1.00 (reference) 1.06 (0.99–1.15) 1.56 (1.39–1.76)
Adjusted HR-1* 1.00 (reference) 1.03 (0.95–1.11) 1.57 (1.38–1.79)
Adjusted HR-2† 1.00 (reference) 0.99 (0.91–1.08) 1.46 (1.25–1.70)
HF Hospitalization
Events 941 (17.7) 900 (14.7) 611 (16.2)
Event rates per 100 person-yrs
(95% CI)
6.9 (6.5–7.4) 6.2 (5.8–6.6) 7.4 (6.8–8.0)
Unadjusted HR 1.00 (reference) 0.83 (0.75–0.92) 1.57 (1.36–1.81)
Adjusted HR-1* 1.00 (reference) 0.81 (0.72–0.90) 1.52 (1.30–1.77)
Adjusted HR-2† 1.00 (reference) 0.85 (0.76–0.96) 1.92 (1.58–2.33)
CV death
Events 881 (16.6) 1,143 (18.7) 801 (21.2)
Event rates per 100 person-yrs
(95% CI)
5.9 (5.6–6.3) 7.3 (6.9–7.7) 8.9 (8.3–9.5)
Unadjusted HR 1.00 (reference) 1.24 (1.13–1.37) 1.50 (1.29–1.74)
Adjusted HR-1* 1.00 (reference) 1.21 (1.10–1.33) 1.55 (1.32–1.82)
Adjusted HR-2† 1.00 (reference) 1.12 (1.01–1.25) 1.35 (1.12–1.62)
All-cause death
Events 1,097 (20.6) 1,349 (22.0) 938 (24.9)
Event rates per 100 person-yrs
(95% CI)
7.4 (7.0–7.8) 8.6 (8.2–9.1) 10.4 (9.8–11.1)
Unadjusted HR 1.00 (reference) 1.20 (1.10–1.30) 1.44 (1.25–1.65)
Adjusted HR-1* 1.00 (reference) 1.18 (1.08–1.28) 1.48 (1.29–1.71)
Adjusted HR-2† 1.00 (reference) 1.13 (1.02–1.24) 1.30 (1.10–1.53)
Values are n (%), median (IQR), or mean  SD. Events are reported as n (%) and as rate per 100 patient-years
(95% CI). Primary outcome was tested for competing risk of all non-CV death; ﬁrst hospitalization for HF was
tested for competing risk of all-cause death; and CV death was tested for competing risk of all non-CV death. All
models were adjusted for region and randomized treatment at baseline. *Adjusted for age, sex, HR, SBP, BMI, NT-
proBNP, eGFR, LVEF, and NYHA functional class. †Adjusted for age, sex, HR, SBP, BMI, NT-proBNP, eGFR, LVEF,
NYHA functional class, per capita income, education index, hospital bed density, and health worker density.
CI ¼ conﬁdence interval; CV ¼ cardiovascular; other abbreviations as in Table 1.
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341conducted using Stata version 14 software (StataCorp,
College Station, Texas).
RESULTS
Overall, 15,126 patients from 54 countries were
included (Table 1, Online Table S1). The median Gini
coefﬁcient was 35.1 (range 25.9 to 64.8; 25th and 75th
percentile: 31.9 and 40.9, respectively). The mean
was 38.1 (9). The highest Gini coefﬁcient tertile (ter-
tile: 3; coefﬁcient: >41; greatest inequality) included
3,772 patients in 17 countries from 4 of the 5 global
regions (North America was excluded) (Figure 1). The
middle tertile (33 to 41) included 6,124 individuals in
19 countries from all 5 regions, and the lowest tertile
(tertile: 1; coefﬁcient: <33; least inequality) included
5,320 patients in 18 countries from 3 of the 5 regions
(North America and Latin America were excluded)
(Figure 1).
As the Gini coefﬁcient increased, the human
development index, the per capita income, the pro-
portion of GDP spent on health care, and the hospital
bed density decreased (Table 1).
BASELINE CHARACTERISTICS. Patient characteris-
tics varied considerably by income inequality (Table 1).
A higher proportion of patients in Gini tertile 3 coun-
tries were women (24.8% vs. 21.0%, respectively, in
tertile 1, and 20.8%, respectively, in tertile 2). Patients
in Gini tertile 3 countries were younger (61 vs. 66 and
63 years of age, respectively), and fewer were obese
(23.7% vs. 34.8% and 30.5%, respectively). Gini tertile
3 countries had the highest proportion of people who
never smoked and lower consumption of alcohol,
whereas tertile 1 countries had the highest proportions
of smokers and heavier consumers of alcohol.
COMORBIDITIES. Gini tertile 3 countries had the
lowest prevalence of all recorded comorbid condi-
tions, including hypertension, diabetes, atrial ﬁbril-
lation, stroke, chronic obstructive pulmonary disease,
and renal disease (Table 1). By contrast, Gini tertile 1
countries had the highest prevalence of all comorbid
conditions, with the single exception of unstable
angina (but not myocardial infarction [MI]), which
was slightly more common in tertile 2 than in tertile 1
countries.
HEART FAILURE CHARACTERISTICS. In keeping
with the pattern of comorbidity, Gini tertile 3 patients
were the least likely to have HF caused by ischemia
(Table 1). Gini tertile 3 patients had the highest pro-
portion of patients with a more recent diagnosis of
HF, although all groups had a similar proportion of
patients with a prior HF hospitalization. Gini tertile 3
patients had the highest proportion of patients inNYHA functional classes I/II and the highest (best)
Kansas City Cardiomyopathy Questionnaire scores.
LVEF differed little across Gini tertiles. However, the
median NT-proBNP concentration was highest in Gini
tertile 3 patients (1,500 pg/ml; IQR: 803 to 3,130 pg/
ml), and the lowest level was seen in tertile 1 patients
(1,358 pg/ml; IQR: 766 to 2,540 pg/ml).
Gini tertile 3 patients had the lowest prevalence of
dyspnea on effort, paroxysmal nocturnal dyspnea,
third heart sound, and peripheral edema. Patients in
tertile 3 also had the lowest SBP (120 vs. 125 mm Hg,
respectively, in tertile 1, and 122 mm Hg in tertile 2).
Gini tertile 3 patients had the highest average eGFR
level, and tertile 1 patients had the lowest eGFR
(Table 1).
FIGURE 2 Cumulative Incidence Plots
Cumulative incidence plot of (A) primary composite outcome; (B) hospitalization for HF; (C) cardiovascular death; and (D) Kaplan-Meier plot
of all-cause death. HF ¼ heart failure.
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342BASELINE DRUGS, DEVICES, AND OTHER THERAPIES.
Gini tertile 3 patients were least often treated with a
diuretic and most often treated with a mineralocorti-
coid receptor antagonist and digoxin (despite the
lower prevalence of atrial ﬁbrillation). Pre-trial use of
an ARB (instead of an ACE inhibitor) was most com-
mon in tertile 3 countries (Table 1). Use of devices was
lowest in tertile 3 patients, who had the use of cardiac
resynchronization therapy with a pacemaker (CRT-P)
or a deﬁbrillator (CRT- D) was 2.7%, and the use of an
implantable cardioverter-deﬁbrillator or CRT-D was
4.4%, respectively; whereas the use of these devices
was intermediate in tertile 2 patients (6.8% and 16.1%,
respectively) and highest in individuals in tertile 1
countries (8.3% and 21.3%, respectively). Prior coro-
nary revascularization (and statin therapy) showed
similar patterns (Table 1).
COMPOSITE OUTCOME AND MORTALITY. Patients in
Gini tertile 3 had the highest rate of primary com-
posite outcome (13.7 per 100 person-years), and the
rate was intermediate in tertile 2 (11.7 per 100
person-years) and lowest in tertile 1 (10.9 per 100person-years) (Table 2, Figure 2). This trend was also
observed for both of the rates of cardiovascular and
all-cause death, which were highest in tertile 3 pa-
tients (8.9 and 10.4, respectively) and lowest in tertile
1 patients (5.9 and 7.4, respectively) (Table 2, Figure 2).
In the model that was adjusted for conventional
prognostic variables, including NT-proBNP, patients
in Gini tertile 3 remained at signiﬁcantly higher risk of
the primary composite outcome (57% higher risk) and
of cardiovascular and all-cause death (55% and 48%
higher, respectively) (Table 2).
When country per capita income, education index,
hospital bed density, and health worker density were
added to the multivariate models, the elevated risk in
Gini tertile 3 patients was attenuated but remained
signiﬁcant (46%, 35%, and 30% higher for the primary
composite outcome, cardiovascular death, and all-
cause mortality, respectively) (Table 2). When the
Gini coefﬁcient was considered a continuous rather
than a categorical variable, it remained an indepen-
dent predictor of outcomes. Each 10-point increase in
Gini coefﬁcient was associated with a higher risk of
FIGURE 3 Multivariate Model of Predictors of Cardiovascular Death in HF
wOn a scale of 0 to 100; *for eGFR <90 ml/min/1.73 m2. Hatched bars ¼ statistically nonsigniﬁcant values. BMI ¼ body mass index; eGFR ¼ estimated glomerular
ﬁltration rate; HF ¼ heart failure; LnNT proBNP ¼ log transformed N -terminal pro-B-type natriuretic peptide; LVEF ¼ left ventricular ejection fraction; MI ¼
myocardial infarction; SBP ¼ systolic blood pressure; US$ ¼ United States dollars.
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343cardiovascular death (HR: 1.16; 95% conﬁdence in-
terval [CI]: 1.04 to 1.29; p ¼ 0.005) and death from any
cause (HR: 1.15; 95% CI: 1.04 to 1.26; p ¼ 0.006)
(Online Table S2, Figure 3). As seen in Figure 3, the
impact of a 10-point increase in Gini coefﬁcient on
cardiovascular death was greater than that of most
other predictive variables, including advancing age
and previous MI.
HOSPITAL ADMISSION FOR HEART FAILURE. The
unadjusted rate of HF hospitalization was highest in
Gini tertile 3 patients but intermediate in tertile 1
rather than tertile 2 patients, as it was for the other
outcomes. In adjusted model 2, risk of hospital
admission for HF was 92% higher in Gini tertile 3 than
in tertile 1 patients (HR: 1.92; 95% CI: 1.58 to 2.33)
(Table 2).
DISCUSSION
In this study of 15,126 HFrEF patients from 54 coun-
tries, a statistically signiﬁcant and clinically sub-
stantial association was found between income
inequality and patient characteristics, and disease
outcomes. These differences persisted after adjust-
ments were made for recognized, patient-level prog-
nostic variables, as well as for country per capita
income.Over the past 20 years, a substantial body of evi-
dence has accrued in support of an association
between income inequality and a variety of mea-
surements of population health. The income
inequality hypothesis states that an individual’s
health is affected not only by his or her own income
but also by the distribution of income in that per-
son’s society, especially in high-income countries.
Consistent with this hypothesis, countries sharing
the same GDP may have quite different health out-
comes, reﬂecting the distribution of income within
those societies. That is, it appears that it is not only the
wealth of a society but the distribution of wealth
within that society that inﬂuences health. Although
these relationships are well established for broad
health outcomes such as childhood and overall mor-
tality, there are few studies of speciﬁc diseases,
especially cardiovascular disease (CVD). However, in
one analysis involving 78 countries, income inequality
was independently and positively associated with
disability-adjusted life years and mortality related to
coronary heart disease (CHD) and coronary risk factors
(18). In another investigation, conﬁned to the United
States, a state-level analysis of the National Longitu-
dinal Mortality Study showed that a 0.1-U higher
Gini coefﬁcient predicted a 1% higher probability of
dying from CHD (19). The present study extended this
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344examination of the relationship between income
disparity and cardiovascular health to HF.
The baseline characteristics, medical history, and
background treatment of patients differed markedly
according to income inequality but perhaps not
predictably or intuitively, given the association be-
tween higher Gini coefﬁcient and worse outcomes.
For example, patients in countries with the highest
Gini coefﬁcient (tertile 3; greatest income inequality)
were, on average, 5 years younger than those in the
lowest tertile countries, and they were more often
women who had less comorbidity, had an ischemic
cause less often, had HF more recently diagnosed,
had a better NYHA functional class proﬁle and
Kansas City Cardiomyopathy Questionnaire score,
and had the highest mean eGFR. These are all fea-
tures that were expected to track with better rather
than worse outcomes, which could be attributable to
the fact that patients in Gini tertile 3 were younger
(20). Indeed, only a few variables associated with a
poor prognosis were more unfavorable in the Gini
coefﬁcient tertile 3 patients, including an average
LVEF that was lower (1.9%) in tertile 3 patients
than in tertile 1 patients, as was SBP (5.2 mm Hg),
whereas median NT-proBNP levels were somewhat
higher (þ142 pg/ml). There were also some treat-
ment differences among the groups that were more
expected, for example, digoxin (which is inexpen-
sive) was used most often in tertile 3 patients,
whereas devices (which are more expensive) were
used much less often.
Even after correcting for patient-level biological
characteristics known to predict outcomes, including
the most powerful of these, NT-proBNP, patients in
Gini tertile 3 had considerably higher mortality than
those in tertile 1. Indeed, the adjusted HR was 1.48
(95% CI: 1.29 to 1.71) for all-cause death and 1.55 (95%
CI: 1.32 to 1.82) for death from cardiovascular causes.
Because population health and life-expectancy are
also associated with overall country afﬂuence, per
capita income, which attenuated but did not eliminate
the relationship between income disparity and mor-
tality (with a remaining excess risk ranging from 20%
to 30%), was also adjusted for. This disconnect be-
tween mortality and clinical presentation in Gini ter-
tile 3 is difﬁcult to explain but is most likely a function
of the unfavorable effects of income inequality.
Additional adjustments for education index, hos-
pital bed density, and physician density also did not
attenuate the greater risk of the composite outcome
among patients in Gini tertile 3, with a fully adjusted
HR of 1.46 (95% CI: 1.25 to 1.70). When the risk of HF
hospitalization alone was examined (but accounting
for the competing risk of death), it was also found tobe highest in countries with the greatest income
disparity. Those countries also had the lowest bed
density, suggesting that admission rates are not just a
function of bed availability.
The large size of the “effect” of income inequality
on HF outcomes is worthy of comment. The adjusted
risks of the fatal outcomes were approximately 20%
to 30% higher in individuals living in the tertile of
countries with the widest income distribution. This
magnitude of differences was similar to or greater
than that attributable to other major comorbidities
such as diabetes or previous MI. The risk associated
with a 10-U increase in Gini coefﬁcient was also
analyzed, noting that the differences between the
median coefﬁcient in tertiles 1 and 3 was 20 U. The
excess risk for cardiovascular mortality per 10-U
increase in Gini coefﬁcient was 16%, similar to the
risk associated with a 10% decrease in LVEF, a
decrease of 27 mm Hg in SBP, or a decrease of 27 ml/
min per 1.73 m2 in eGFR.
Countries were divided according to thirds of Gini
coefﬁcient, giving tertiles of <33%, 33% to 41%, and
>41%. There is generally no consensus for the cate-
gorization of nations according to Gini coefﬁcient,
although in a study by Kim and colleagues (18), which
examined CHD and stroke, countries were divided
into “low” (<0.38), “medium” (95% CI: 0.38 to 0.55),
and “high” (>0.55) Gini coefﬁcient groups (using a
scale of 0 to 1.0). In a meta-analysis of 9 multilevel
longitudinal studies including nearly 60 million par-
ticipants, Kondo et al. (21) reported a relative risk of
1.08 (95% CI: 1.06 to 1.10) for all-cause mortality per
0.05-U increase in Gini coefﬁcient (using a scale of
0 to 1.0). Analysis of the present study showed an
equivalent increase in Gini coefﬁcient (5 points on a
scale of 0 to 100) was associated with an HR of 1.07
(95% CI: 1.02 to 1.12; p ¼ 0.006); that is, an excess risk
of similar magnitude.
Of course, the key question about the present ﬁnd-
ings, and those about income inequality health hypoth-
esis generally, is why should greater income disparity
be associated with worse health outcomes? Many
theories have been expounded. One way to consider
these outcomes is under the broad headings of “societal-
structural” and “psychosocial” explanations.
The “societal-structural” explanations are numerous
and complex, and not all are necessarily relevant to
outcomes in patients with an established clinical con-
dition (as opposed to the future development of dis-
ease) (22,23). Many of these explanations focus on the
corrosive effects of income inequality on society,
leading to loss of social cohesion and divergence be-
tween the interests of the rich and those of the poor. It
is argued that income inequality leads to the decreased
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: HF poses an
enormous economic burden on society. It is the leading cause of
hospitalization in Western countries and is steadily increasing in
prevalence (and is especially concerning in younger people) in
developing countries. In countries with prominent levels of in-
come inequality, unfavorable social actors coupled with inade-
quate and inefﬁcient public spending on health care may present
considerable barriers not only to the prevention of CVD (the
focus of most studies to date) but also to the improvement of
outcomes in patients with established and chronic diseases such
as HF.
TRANSLATIONAL OUTLOOK: If indeed income inequality
does inﬂuence HF outcomes, both developing and developed
nations need to consider how their public health policies can be
modiﬁed to more effectively tackle this growing global epidemic.
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345willingness of societies to invest in social services and
welfare programs, broad access to health care services,
and safety nets (24,25). These effects may lead to dis-
tortions of health care priorities and spending and can
be exacerbated by geographical concentrations of hos-
pitals and physicians in more afﬂuent areas, with
provision of medically unnecessary services and per-
formance of discretionary procedures in these areas.
Conversely, there may be underinvestment in health
care infrastructure and resources in areas of greater
need, with reduced access to and affordability of health
care for the neediest (25). Potentially, each of these
factors could lead to a higher prevalence of disease,
delayed care, more advanced disease at presentation,
more preventable hospital admissions, and ultimately,
more premature deaths. It is also easy to see how a
syndrome as complicated as HF, with its need for
integration of primary and secondary health care ser-
vices, multidisciplinary management programs, appro-
priate exercise prescription, complex polypharmacy
and attendant electrolyte monitoring, tailored treat-
ment of physical and psychological comorbidity,
appropriate selection of devices, and ultimately, pro-
vision of palliative care may be particularly affected by
gaps in services and aggravated by failure of social and
family networks related to loss of social cohesion (26).
Some of these societal issues may also be greater in
low- and middle-income countries undergoing
epidemiologic transitions from infectious diseases to
noncommunicable diseases (27). Here, health strate-
gies and policies need to change, but these countries
often display a high level of income disparity, despite
(or because of) accelerated economic growth in many
cases (28).
Among the psychosocial explanations, the one that
is of most interest in HF is the belief that chronic
stress as a consequence of the income inequality
described above has detrimental psychoneuroendo-
crine effects (18). There is long-standing evidence
that stress may be involved in at least some types of
CVDs. For example, in the INTERHEART study,
Rosengren et al. (29) found that psychosocial
stressors were associated with a higher risk of acute
MI. Chronic stress is associated with memory
impairment, anxiety, and depression, all of which are
common in HF and potentially harmful because of
adverse effects on adherence and self-management
(30,31). Moreover, recent evidence has suggested
even more widespread biological consequences of
stress including reduced immune responses and
impaired endothelial function (32).
STUDY STRENGTHS AND LIMITATIONS. To the best
of the present authors’ knowledge, the current studyis the ﬁrst to investigate the association between in-
come inequality and outcomes in HF (or any chronic
disease) transnationally. However, the present study
is based on a highly selected clinical trial population
recruited from speciﬁc centers and may not neces-
sarily represent the general population.
Not all the countries in this analysis were from
similar income categories, and information on indi-
vidual socioeconomic status was missing, but
adjustment was made for per capita income repre-
senting population-level income for each country.
Accordingly, differences in health care systems were
not adjusted because most of the countries did not
follow any particular health care system (33). An
attempt was made to make up for those shortcomings
to a certain degree by including information about
hospital bed density and health worker density per
1,000 population. Patients were mandated by proto-
col to have been receiving ACE inhibitor (or ARB)
therapy and beta-blocker therapy at the time of
screening. There was also poor representation from
Africa in the analysis (only patients from South Africa
were included). A measurement that might have
supported or refuted a “psychosocial” explanation for
the association between greater income disparity and
poor outcomes was lacking.
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